Y-mAbs Therapeutics, Inc.
YMAB
$4.73
-$0.18-3.67%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.38% | -8.99% | 1.84% | 12.62% | 29.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.38% | -8.99% | 1.84% | 12.62% | 29.96% |
| Cost of Revenue | 33.59% | -17.10% | -12.31% | 46.84% | 50.89% |
| Gross Profit | -1.32% | -7.85% | 3.99% | 8.64% | 27.21% |
| SG&A Expenses | 21.20% | 20.06% | 4.73% | -10.23% | -15.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.99% | 0.78% | -6.23% | -18.03% | -28.65% |
| Operating Income | -36.43% | -49.76% | 24.87% | 57.23% | 74.57% |
| Income Before Tax | -42.87% | -21.92% | 38.35% | 71.65% | 78.17% |
| Income Tax Expenses | -126.02% | 118.85% | 258.66% | -- | -- |
| Earnings from Continuing Operations | -38.45% | -23.76% | 36.99% | 70.68% | 77.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.45% | -23.76% | 36.99% | 70.68% | 77.58% |
| EBIT | -36.43% | -49.76% | 24.87% | 57.23% | 74.57% |
| EBITDA | -38.72% | -53.20% | 24.85% | 57.85% | 75.20% |
| EPS Basic | -36.43% | -22.46% | 37.15% | 70.66% | 77.55% |
| Normalized Basic EPS | -65.60% | -78.18% | 26.13% | 62.90% | 80.15% |
| EPS Diluted | -35.57% | -21.28% | 37.45% | 70.73% | 77.39% |
| Normalized Diluted EPS | -65.60% | -77.18% | 26.29% | 62.95% | 80.17% |
| Average Basic Shares Outstanding | 1.56% | 0.82% | 0.19% | -0.05% | -0.13% |
| Average Diluted Shares Outstanding | 1.56% | 0.23% | -0.40% | -0.63% | -0.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
